Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors.
Our lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of our proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. We believe that our preliminary Phase 1/2 data from our ongoing clinical trial provide us with clinical proof of concept for our HER2 Boltbody ISAC approach.
Bolt is also advancing additional Boltbody ISAC product candidates targeting CEA and PD-L1.
May 27, 2022
Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022Read More
May 12, 2022
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business HighlightsRead More
April 7, 2022
Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare ConferenceRead More
June 5, 2022 at 9:00 AM EDT
The 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Read More
April 14, 2022 at 3:45 PM EDT
21st Annual Needham Virtual Healthcare Conference Read More
April 8 - April 13, 2022
American Association of Cancer Research (AACR) Annual Meeting 2022 Read More